Skip to main content
Erschienen in: Current HIV/AIDS Reports 6/2022

07.12.2022 | Voluntary Medical Male Circumcision: Progress and Challenges (S Vermund, Section Editor)

Voluntary Medical Male Circumcision to Reduce HIV Acquisition and Transmission

verfasst von: Sten H. Vermund

Erschienen in: Current HIV/AIDS Reports | Ausgabe 6/2022

Einloggen, um Zugang zu erhalten

Abstract

Purpose of Review

This commentary introduces the special Global Health Section on the state of voluntary medical male circumcision (VMMC) programs and current knowledge as to role of VMMC prevention of HIV infection acquisition in men and, indirectly, women.

Recent Findings

Since the first clinical trial of VMMC in Africa was published in 2005, implementation of programs has depended on illuminating best practices and key obstacles in the effort to expand VMMC in areas of high HIV prevalence to reduce HIV acquisition among men, with consequent benefits that uninfected men will not infect others. Global efforts are focused on sub-Saharan Africa, given the favorable expected impact of VMMC deployment where HIV incidence is high and circumcision rates are low.

Summary

With estimated field effectiveness estimated to exceed 60%, reduced HIV risk for circumcised men in sub-Saharan Africa based on a once-only minor surgical intervention provides extraordinary preventive benefits. Where high VMMC rates have been achieved, declining HIV incidence rates may be partially or substantially attributed to VMMC, but this remains to be investigated. Articles in this special section address achievements, obstacles and risks, and plans for future progress in partnership with affected communities.
Literatur
1.
Zurück zum Zitat Williams WB, Wiehe K, Saunders KO, Haynes BF. Strategies for induction of HIV-1 envelope-reactive broadly neutralizing antibodies. J Int AIDS Soc. 2021;24(7):25831. Williams WB, Wiehe K, Saunders KO, Haynes BF. Strategies for induction of HIV-1 envelope-reactive broadly neutralizing antibodies. J Int AIDS Soc. 2021;24(7):25831.
2.
Zurück zum Zitat Zolla-Pazner S, Michael NL, Kim JH. A tale of four studies: HIV vaccine immunogenicity and efficacy in clinical trials. Lancet HIV. 2021;8(7):e449–52.CrossRef Zolla-Pazner S, Michael NL, Kim JH. A tale of four studies: HIV vaccine immunogenicity and efficacy in clinical trials. Lancet HIV. 2021;8(7):e449–52.CrossRef
3.
Zurück zum Zitat Hanke T. New vector and vaccine platforms: mRNA, DNA, viral vectors. Curr Opin HIV AIDS. 2022;17(6):338–44.CrossRef Hanke T. New vector and vaccine platforms: mRNA, DNA, viral vectors. Curr Opin HIV AIDS. 2022;17(6):338–44.CrossRef
4.
Zurück zum Zitat Vermund SH, Tique JA, Cassell HM, Pask ME, Ciampa PJ, Audet CM. Translation of biomedical prevention strategies for HIV: prospects and pitfalls. J Acquir Immune Defic Syndr. 2013;63(1):12–25.CrossRef Vermund SH, Tique JA, Cassell HM, Pask ME, Ciampa PJ, Audet CM. Translation of biomedical prevention strategies for HIV: prospects and pitfalls. J Acquir Immune Defic Syndr. 2013;63(1):12–25.CrossRef
7.
Zurück zum Zitat • Agot K, Onyango, J, Ochillo M, Odoyo-June, E, et al. VMMC Programmatic Successes and Challenges: Western Kenya Case Study. Curr HIV/AIDS Rep. 2022. https://doi.org/10.1007/s11904-022-00644-8. Arguably, VMMC has been most successful in western Kenya and the lessons learned can be informative for all of sub-Saharan Africa and other regions seeking to scale up VMMC programs. • Agot K, Onyango, J, Ochillo M, Odoyo-June, E,  et al. VMMC Programmatic Successes and Challenges: Western Kenya Case Study. Curr HIV/AIDS Rep. 2022. https://​doi.​org/​10.​1007/​s11904-022-00644-8. Arguably, VMMC has been most successful in western Kenya and the lessons learned can be informative for all of sub-Saharan Africa and other regions seeking to scale up VMMC programs.
9.
Zurück zum Zitat Lucas T, Cooney C, Prainito A, Godfrey C, Kiggundu V, Thomas, AG, et al. Consolidated Overview of Notifiable Adverse Events in the U.S. President’s Emergency Plan for AIDS Relief’s Voluntary Medical Male Circumcision Program Through 2020. Curr HIV/AIDS Rep. 2022. https://doi.org/10.1007/s11904-022-00636-8. Lucas T, Cooney C, Prainito A, Godfrey C, Kiggundu V, Thomas, AG, et al. Consolidated Overview of Notifiable Adverse Events in the U.S. President’s Emergency Plan for AIDS Relief’s Voluntary Medical Male Circumcision Program Through 2020. Curr HIV/AIDS Rep. 2022. https://​doi.​org/​10.​1007/​s11904-022-00636-8.
11.
Zurück zum Zitat Gao Y, Yuan T, Zhan Y, Qian HZ, Sun Y, Zheng W, et al. Association between medical male circumcision and HIV risk compensation among heterosexual men: a systematic review and meta-analysis. Lancet Glob Health. 2021;9(7):e932–41.CrossRef Gao Y, Yuan T, Zhan Y, Qian HZ, Sun Y, Zheng W, et al. Association between medical male circumcision and HIV risk compensation among heterosexual men: a systematic review and meta-analysis. Lancet Glob Health. 2021;9(7):e932–41.CrossRef
12.
Zurück zum Zitat • Lin Y, Gao Y, Sun Y, Turner D, Zou H, Vermund SH, et al. Does voluntary medical male circumcision reduce HIV risk in men who have sex with men? Curr HIV/AIDS Rep. 2022. https://doi.org/10.1007/s11904-022-00637-7. Research sponsors should seek a definitive clinical trials answer to the extent to which MSM might benefit from circumcision. •  Lin Y, Gao Y, Sun Y, Turner D, Zou H, Vermund SH, et al. Does voluntary medical male circumcision reduce HIV risk in men who have sex with men? Curr HIV/AIDS Rep. 2022. https://​doi.​org/​10.​1007/​s11904-022-00637-7. Research sponsors should seek a definitive clinical trials answer to the extent to which MSM might benefit from circumcision.
13.
Zurück zum Zitat Bershteyn A, Mudimu E, Platais I, Mwalili S, Zulu JE, et al. Understanding the evolving role of voluntary medical male circumcision as a public health strategy in Eastern and Southern Africa: opportunities and challenges. Curr HIV/AIDS Rep. 2022. https://doi.org/10.1007/s11904-022-00639-5. Bershteyn A, Mudimu E, Platais I, Mwalili S, Zulu JE, et al. Understanding the evolving role of voluntary medical male circumcision as a public health strategy in Eastern and Southern Africa: opportunities and challenges. Curr HIV/AIDS Rep. 2022. https://​doi.​org/​10.​1007/​s11904-022-00639-5.
14.
Zurück zum Zitat Farley TM, Samuelson J, Grabowski MK, Ameyan W, Gray RH, Baggaley R. Impact of male circumcision on risk of HIV infection in men in a changing epidemic context – systematic review and meta-analysis. J Int AIDS Soc. 2020;23(6):e25490.CrossRef Farley TM, Samuelson J, Grabowski MK, Ameyan W, Gray RH, Baggaley R. Impact of male circumcision on risk of HIV infection in men in a changing epidemic context – systematic review and meta-analysis. J Int AIDS Soc. 2020;23(6):e25490.CrossRef
15.
Zurück zum Zitat • Peck, M.E., Lucas, T., Ong, K.S. et al. Defining the Global Research and Programmatic Agenda and Priority Actions for Voluntary Medical Male Circumcision for HIV Prevention. Curr HIV/AIDS Rep (2022). https://doi.org/10.1007/s11904-022-00640-y. Signposting future policy priorities helps both programmatic and investigative planning. • Peck, M.E., Lucas, T., Ong, K.S. et al. Defining the Global Research and Programmatic Agenda and Priority Actions for Voluntary Medical Male Circumcision for HIV Prevention. Curr HIV/AIDS Rep (2022). https://​doi.​org/​10.​1007/​s11904-022-00640-ySignposting future policy priorities helps both programmatic and investigative planning.
16.
Zurück zum Zitat Aguolu OG, Malik AA, Ahmed N, Omer SB. Overcoming vaccine hesitancy for future COVID-19 and HIV vaccines: lessons from measles and HPV vaccines. Curr HIV/AIDS Rep. 2022;19(5):328–43.CrossRef Aguolu OG, Malik AA, Ahmed N, Omer SB. Overcoming vaccine hesitancy for future COVID-19 and HIV vaccines: lessons from measles and HPV vaccines. Curr HIV/AIDS Rep. 2022;19(5):328–43.CrossRef
17.
Zurück zum Zitat Tankwanchi AS, Jaca A, Ndlambe AM, Zantsi ZP, Bowman B, Garrison MM, et al. Non-COVID-19 vaccine hesitancy among migrant populations worldwide: a scoping review of the literature, 2000–2020. Expert Rev Vaccines. 2022;21(9):1269–87.CrossRef Tankwanchi AS, Jaca A, Ndlambe AM, Zantsi ZP, Bowman B, Garrison MM, et al. Non-COVID-19 vaccine hesitancy among migrant populations worldwide: a scoping review of the literature, 2000–2020. Expert Rev Vaccines. 2022;21(9):1269–87.CrossRef
18.
Zurück zum Zitat Nanni A, Meredith S, Gati S, Holm K, Harmon T, Ginsberg A. Strengthening global vaccine access for adolescents and adults. Vaccine. 2017;35(49):6823–7.CrossRef Nanni A, Meredith S, Gati S, Holm K, Harmon T, Ginsberg A. Strengthening global vaccine access for adolescents and adults. Vaccine. 2017;35(49):6823–7.CrossRef
19.
Zurück zum Zitat Guignard A, Praet N, Jusot V, Bakker M, Baril L. Introducing new vaccines in low- and middle-income countries: challenges and approaches. Expert Rev Vaccines. 2019;18(2):119–31.CrossRef Guignard A, Praet N, Jusot V, Bakker M, Baril L. Introducing new vaccines in low- and middle-income countries: challenges and approaches. Expert Rev Vaccines. 2019;18(2):119–31.CrossRef
20.
Zurück zum Zitat Gostin LO, Hodge JG Jr, Bloom BR, El-Mohandes A, Fielding J, Hotez P, et al. The public health crisis of underimmunisation: a global plan of action. Lancet Infect Dis. 2020;20(1):e11–6.CrossRef Gostin LO, Hodge JG Jr, Bloom BR, El-Mohandes A, Fielding J, Hotez P, et al. The public health crisis of underimmunisation: a global plan of action. Lancet Infect Dis. 2020;20(1):e11–6.CrossRef
21.
Zurück zum Zitat Sauer M, Vasudevan P, Meghani A, Luthra K, Garcia C, Knoll MD, Privor-Dumm L. Situational assessment of adult vaccine preventable disease and the potential for immunization advocacy and policy in low- and middle-income countries. Vaccine. 2021;39(11):1556–64.CrossRef Sauer M, Vasudevan P, Meghani A, Luthra K, Garcia C, Knoll MD, Privor-Dumm L. Situational assessment of adult vaccine preventable disease and the potential for immunization advocacy and policy in low- and middle-income countries. Vaccine. 2021;39(11):1556–64.CrossRef
22.
Zurück zum Zitat Levin A, Boonstoppel L, Brenzel L, Griffiths U, Hutubessy R, Jit M, et al. WHO-led consensus statement on vaccine delivery costing: process, methods, and findings. BMC Med. 2022;20(1):88.CrossRef Levin A, Boonstoppel L, Brenzel L, Griffiths U, Hutubessy R, Jit M, et al. WHO-led consensus statement on vaccine delivery costing: process, methods, and findings. BMC Med. 2022;20(1):88.CrossRef
Metadaten
Titel
Voluntary Medical Male Circumcision to Reduce HIV Acquisition and Transmission
verfasst von
Sten H. Vermund
Publikationsdatum
07.12.2022
Verlag
Springer US
Erschienen in
Current HIV/AIDS Reports / Ausgabe 6/2022
Print ISSN: 1548-3568
Elektronische ISSN: 1548-3576
DOI
https://doi.org/10.1007/s11904-022-00631-z

Weitere Artikel der Ausgabe 6/2022

Current HIV/AIDS Reports 6/2022 Zur Ausgabe

Voluntary Medical Male Circumcision: Progress and Challenges (S Vermund, Section Editor)

Does Voluntary Medical Male Circumcision Reduce HIV Risk in Men Who Have Sex with Men?

Voluntary Medical Male Circumcision: Progress and Challenges (S Vermund, Section Editor)

Voluntary Medical Male Circumcision for HIV Prevention: a Global Overview

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag

Triglyzeridsenker schützt nicht nur Hochrisikopatienten

10.05.2024 Hypercholesterinämie Nachrichten

Patienten mit Arteriosklerose-bedingten kardiovaskulären Erkrankungen, die trotz Statineinnahme zu hohe Triglyzeridspiegel haben, profitieren von einer Behandlung mit Icosapent-Ethyl, und zwar unabhängig vom individuellen Risikoprofil.

Gibt es eine Wende bei den bioresorbierbaren Gefäßstützen?

In den USA ist erstmals eine bioresorbierbare Gefäßstütze – auch Scaffold genannt – zur Rekanalisation infrapoplitealer Arterien bei schwerer PAVK zugelassen worden. Das markiert einen Wendepunkt in der Geschichte dieser speziellen Gefäßstützen.

Vorsicht, erhöhte Blutungsgefahr nach PCI!

10.05.2024 Koronare Herzerkrankung Nachrichten

Nach PCI besteht ein erhöhtes Blutungsrisiko, wenn die Behandelten eine verminderte linksventrikuläre Ejektionsfraktion aufweisen. Das Risiko ist umso höher, je stärker die Pumpfunktion eingeschränkt ist.

Wie managen Sie die schmerzhafte diabetische Polyneuropathie?

10.05.2024 DDG-Jahrestagung 2024 Kongressbericht

Mit Capsaicin-Pflastern steht eine neue innovative Therapie bei schmerzhafter diabetischer Polyneuropathie zur Verfügung. Bei therapierefraktären Schmerzen stellt die Hochfrequenz-Rückenmarkstimulation eine adäquate Option dar.

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.